헤파린이 결합된 피브린젤에서 방출된 표피세포성장인자를 이용한 피부재생

Abstract

The current study was designed to evaluate the feasibility of using basic fibroblast growth factor (bFGF) delivered from heparin-conjugated fibrin gel (HCF) for skin regeneration. HCF was used as both a vehicle to release bFGF locally in the skin injury sites and a scaffold for skin regeneration. HCF (0.2 ml/animal) containing bFGF (50 μg/ml) was implanted to full thickness skin defects (1.5 x 1.5 cm2) in mice. Mice with no treatment served as a negative control. HCF containing no bFGF and normal fibrin gel, normal fibrin gel containing bFGF and free heparin were also implanted to skin defects. All animal in the group of fibrin gel containing bFGF and free heparin died immediately after skin injury due to failure in arrest of bleeding caused by free heparin. All animals in other groups survived. Histological stainng with hematoxylin and eosin and masson's trichrome, immunohistochemistry for von willebrand factor, smooth muscle α-actin, invoulcrin, and proliferating cell nuclear antigen, and epidermal thickness evaluation were performed. Neovascularization was significantly enhanced and epidermal thickness was much larger in HCF containing bFGF group compared to other groups. Cell proliferation in neodermis was much higher in HCF containing bFGF group than in other groups. The enhanced skin regeneration by bFGF released from HCF may be mediated by enhanced neovascularization and cell proliferation in neodermis. bFGF delivery using HCF would be a valuable molality for skin regeneration.